A Smarter Default: Why the FDA’s New Evidence Pathway Reflects How Science Actually Works

The recent shift by the Food and Drug Administration toward a more flexible default for drug approval—one adequate and well-controlled clinical trial supported by confirmatory evidence—represents not a departure from scientific rigor, but a long-overdue alignment with modern discovery. For rare disease communities in particular, this change acknowledges a reality patients and advocates have lived with for decades: evidence does not arrive neatly packaged, and progress rarely follows a straight line.

This new default option closely mirrors the intent behind Promising Pathway 2.0, legislation I helped draft to formally recognize that real-world data, natural history, mechanistic insight, and patient-centered outcomes are not ancillary to science—they are part of it. Especially in rare and ultra-rare diseases, where populations are small and heterogeneity is high, insisting on duplicative pivotal trials has often functioned less as a safeguard and more as a barrier.

For small and mid-sized biotech companies, the historical expectation of running two large trials can be financially prohibitive, discouraging investment in precisely the areas of highest unmet need. For patients, it can mean years of delay—or no development at all. Reducing unnecessary redundancy de-risks innovation without de-risking patients, provided the totality of evidence is evaluated with discipline, transparency, and accountability.

But any discussion of flexibility inevitably draws criticism.

There will always be skeptics who argue that if evidence does not conform to the way it has always been generated, it is somehow less scientific. This mindset treats science as a closed box—defined by precedent rather than discovery. That is not rigor. That is resistance to change.

Science evolves because it challenges its own assumptions. Many foundational advances in medicine did not emerge from perfectly linear hypotheses, but from observation, anomaly, and curiosity. In rare disease research, discovery often begins not with a protocol, but with patients.

Within the SYNGAP1 community, one of the most consequential insights did not originate from a prespecified clinical endpoint. It began with a real-world observation: patients consistently exhibited unusually high pain thresholds. That finding did not fit prevailing theories, nor did it align with where the field had narrowly focused its attention—the hippocampus. Rather than dismissing the observation because it fell outside conventional frameworks, we worked backward to understand why.

What emerged was a critical shift in understanding. SynGAP expression was found to be profoundly reduced in the frontal somatosensory cortex—a region essential for sensory processing—explaining why pain signals were not relayed or interpreted in typical ways. This revealed something the field had missed: SynGAP protein is not functionally uniform across the brain. Its impact varies by region. That insight did not arise from rigid adherence to existing models. It arose from listening, observing, and then measuring.

This is precisely the kind of learning that modern regulatory frameworks must be capable of incorporating.

Critics often claim that flexibility in evidence standards weakens science. The opposite is true. What weakens science is clinging to methodology as dogma when better tools, deeper biological understanding, and richer real-world data are available. Requiring two trials does not rescue poor design, inappropriate endpoints, or biologically incoherent hypotheses. Repetition is not a substitute for credibility.

In rare diseases, this rigidity is especially harmful. Efficacy does not always look dramatic on paper. Stabilization can be benefit. Slowing decline can be transformative. Modest functional improvements—sustained over time—can fundamentally alter quality of life for patients and families. A framework incapable of recognizing those realities risks declaring therapies ineffective simply because they do not conform to benchmarks designed for entirely different conditions.

This is where real-world evidence, when developed prospectively and governed by strong advocacy standards, becomes indispensable. Longitudinal registries, caregiver-reported outcomes, biomarker trajectories, and natural history studies provide essential context for interpreting clinical signals. Promising Pathway 2.0 was designed to integrate these data streams responsibly—not to lower expectations, but to make them relevant.

Importantly, flexibility must be paired with accountability. Patient communities are not asking for shortcuts. They are asking for partnership. Transparency, post-market surveillance, and continuous evidence generation are non-negotiable. Accelerated pathways must include a commitment to learn after approval, adjust when needed, and act decisively if benefit fails to materialize.

The FDA’s decision to change the default—not eliminate rigor, but redefine how it is achieved—matters more than it may appear. Defaults shape behavior. They influence investment, trial design, and whether innovators even attempt to develop therapies for small populations. By signaling that one well-designed trial, supported by coherent confirmatory evidence, can be sufficient, the agency is aligning regulation with how science and medicine now function.

There will always be cynics. There always have been. But science has never advanced by waiting for consensus from those most invested in preserving the status quo. It advances because someone is willing to acknowledge that discovery is messy, evidence accumulates unevenly, and patients cannot wait for perfection.

A smarter, more integrated evidence framework does not abandon science. It reflects it. And for rare disease patients, it may finally move the system from asking whether progress is possible to asking how fast we are willing to let it happen.